<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

DLBCL PDX Models with Diverse Genotypes for BTKi Testing

Bruton's tyrosine kinase (BTK) activation is a major oncogenic driver for various B cell-derived lymphoid cancers. The BTK inhibitor ibrutinib has been approved for a range of malignancies (e.g. mantle cell lymphoma, chronic lymphocytic leukemia), and has also shown encouraging efficacy in the ABC subtype, but not GCB subtype, of DLBCL.